Skip to main content
Top
Published in: Respiratory Research 1/2020

Open Access 01-12-2020 | Chronic Obstructive Lung Disease | Research

The correlation between CYP4F2 variants and chronic obstructive pulmonary disease risk in Hainan Han population

Authors: Yipeng Ding, Yixiu Yang, Quanni Li, Qiong Feng, Dongchuan Xu, Cibing Wu, Jie Zhao, Xiaoli Zhou, Huan Niu, Ping He, Jianfang Liu, Hongxia Yao

Published in: Respiratory Research | Issue 1/2020

Login to get access

Abstract

Background

Chronic obstructive pulmonary disease (COPD) is a complex pulmonary disease. Cytochrome P450 family 4 subfamily F member 2 (CYP4F2) belongs to cytochrome P450 superfamily of enzymes responsible for metabolism, its single nucleotide polymorphisms (SNPs) were reported to be involved in metabolism in the development of many diseases. The study aimed to assess the relation between CYP4F2 SNPs and COPD risk in the Hainan Han population.

Method

We genotyped five SNPs in CYP4F2 in 313 cases and 508 controls by Agena MassARRAY assay. The association between CYP4F2 SNPs and COPD risk were assessed by χ2 test and genetic models. Besides, logistic regression analysis was introduced into the calculation for odds ratio (OR) and 95% confidence intervals (CIs).

Results

Allele model analysis indicated that rs3093203 A was significantly correlated with an increased risk of COPD. Also, rs3093193 G and rs3093110 G were associated with a reduced COPD risk. In the genetic models, we found that rs3093203 was related to an increased COPD risk, while rs3093193 and rs3093110 were related to a reduced risk of COPD. After gender stratification, rs3093203, rs3093193 and rs3093110 showed the association with COPD risk in males. With smoking stratification, rs3093144 was significantly associated with an increased risk of COPD in smokers. CYP4F2 SNPs were significantly associated with COPD risk.

Conclusions

Our findings illustrated potential associations between CYP4F2 polymorphisms and COPD risk. However, large-scale and well-designed studies are needed to determine conclusively the association between the CYP4F2 SNPs and COPD risk.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, Casey DC, Charlson FJ, Chen AZ. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1545–602.CrossRef Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, Casey DC, Charlson FJ, Chen AZ. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1545–602.CrossRef
2.
go back to reference Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5:020415. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5:020415.
3.
go back to reference Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. NCHS Data Brief. 2018:1–8. Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. NCHS Data Brief. 2018:1–8.
4.
go back to reference Wheaton AG, Cunningham TJ, Ford ES, Croft JB. Employment and activity limitations among adults with chronic obstructive pulmonary disease — United States, 2013. Morb Mortal Wkly Rep. 2015;64:289–95. Wheaton AG, Cunningham TJ, Ford ES, Croft JB. Employment and activity limitations among adults with chronic obstructive pulmonary disease — United States, 2013. Morb Mortal Wkly Rep. 2015;64:289–95.
5.
go back to reference Ford ES, Mannino DM, Wheaton AG, Giles WH, Presley-Cantrell L, Croft JB. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and nutrition examination surveys from 1988-1994 to 2007-2010. Chest. 2013;143:1395–406.CrossRef Ford ES, Mannino DM, Wheaton AG, Giles WH, Presley-Cantrell L, Croft JB. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and nutrition examination surveys from 1988-1994 to 2007-2010. Chest. 2013;143:1395–406.CrossRef
6.
go back to reference Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53.
7.
go back to reference Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, Li Y, Wang L, Liu Y, Yin P. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the global burden of disease study 2013. Lancet. 2016;387:251–72.CrossRef Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, Li Y, Wang L, Liu Y, Yin P. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the global burden of disease study 2013. Lancet. 2016;387:251–72.CrossRef
8.
go back to reference Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y. Prevalence of chronic obstructive pulmonary disease in China a large, population-based survey. Am J Respir Crit Care Med. 2007;176:753–60.CrossRef Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y. Prevalence of chronic obstructive pulmonary disease in China a large, population-based survey. Am J Respir Crit Care Med. 2007;176:753–60.CrossRef
9.
go back to reference Bi Y, Jiang Y, He J, Xu Y, Wang L, Xu M, Zhang M, Li Y, Wang T, Dai M. Status of cardiovascular health in Chinese adults. J Am Coll Cardiol. 2015;65:1013–25.CrossRef Bi Y, Jiang Y, He J, Xu Y, Wang L, Xu M, Zhang M, Li Y, Wang T, Dai M. Status of cardiovascular health in Chinese adults. J Am Coll Cardiol. 2015;65:1013–25.CrossRef
10.
go back to reference Wang B, Zhou H, Yang J, Xiao J, Liang B, Li D, Zhou H, Zeng Q, Fang C, Rao Z. Association of HHIP polymorphisms with COPD and COPD-related phenotypes in a Chinese Han population. Gene. 2013;531:101–5.CrossRef Wang B, Zhou H, Yang J, Xiao J, Liang B, Li D, Zhou H, Zeng Q, Fang C, Rao Z. Association of HHIP polymorphisms with COPD and COPD-related phenotypes in a Chinese Han population. Gene. 2013;531:101–5.CrossRef
11.
go back to reference Kim WJ, Lee MK, Shin C, Cho NH, Lee SD, Oh YM, Sung J. Genome-wide association studies identify locus on 6p21 influencing lung function in the Korean population. Respirology. 2014;19:360–8.CrossRef Kim WJ, Lee MK, Shin C, Cho NH, Lee SD, Oh YM, Sung J. Genome-wide association studies identify locus on 6p21 influencing lung function in the Korean population. Respirology. 2014;19:360–8.CrossRef
12.
go back to reference Uslu A, Ogus C, Ozdemir T, Bilgen T, Tosun O, Keser I. The effect of CYP1A2 gene polymorphisms on theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients. J Biochem Mol Biol. 2010;43:530–4. Uslu A, Ogus C, Ozdemir T, Bilgen T, Tosun O, Keser I. The effect of CYP1A2 gene polymorphisms on theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients. J Biochem Mol Biol. 2010;43:530–4.
13.
go back to reference Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, Van Ginneken B, Young R, Zeiglerheitbrock L. Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nat Genet. 2019;51:494–505.CrossRef Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, Van Ginneken B, Young R, Zeiglerheitbrock L. Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nat Genet. 2019;51:494–505.CrossRef
14.
go back to reference Zhu L, He Y, Niu F, Yan M, Li J, Yuan D, Jin T. Polymorphisms of drug-metabolizing enzyme CYP2E1 in Chinese Uygur population. Medicine (Baltimore). 2018;97:e9970.CrossRef Zhu L, He Y, Niu F, Yan M, Li J, Yuan D, Jin T. Polymorphisms of drug-metabolizing enzyme CYP2E1 in Chinese Uygur population. Medicine (Baltimore). 2018;97:e9970.CrossRef
15.
go back to reference Cao P, Zhao Q, Shao Y, Yang H, Jin T, Li B, Li H. Genetic polymorphisms of the drug-metabolizing enzyme CYP2J2 in a Tibetan population. Medicine (Baltimore). 2018;97:e12579.CrossRef Cao P, Zhao Q, Shao Y, Yang H, Jin T, Li B, Li H. Genetic polymorphisms of the drug-metabolizing enzyme CYP2J2 in a Tibetan population. Medicine (Baltimore). 2018;97:e12579.CrossRef
16.
go back to reference Wang C, Chen F, Liu Y, Xu Q, Guo L, Zhang X, Ruan Y, Shi Y, Shen L, Li M, et al. Genetic Association of Drug Response to Erlotinib in Chinese advanced non-small cell lung Cancer patients. Front Pharmacol. 2018;9:360.CrossRef Wang C, Chen F, Liu Y, Xu Q, Guo L, Zhang X, Ruan Y, Shi Y, Shen L, Li M, et al. Genetic Association of Drug Response to Erlotinib in Chinese advanced non-small cell lung Cancer patients. Front Pharmacol. 2018;9:360.CrossRef
17.
go back to reference Van Engen CE, Ofman R, Dijkstra IME, Van Goethem TJ, Verheij E, Varin J, Vidaud M, Wanders RJA, Aubourg P, Kemp S. CYP4F2 affects phenotypic outcome in adrenoleukodystrophy by modulating the clearance of very long-chain fatty acids. Biochim Biophys Acta. 1862;2016:1861–70. Van Engen CE, Ofman R, Dijkstra IME, Van Goethem TJ, Verheij E, Varin J, Vidaud M, Wanders RJA, Aubourg P, Kemp S. CYP4F2 affects phenotypic outcome in adrenoleukodystrophy by modulating the clearance of very long-chain fatty acids. Biochim Biophys Acta. 1862;2016:1861–70.
18.
go back to reference Wang H, Qiu T, Shi J, Liang J, Wang Y, Quan L, Zhang Y, Zhang Q, Tao K. Gene expression profiling analysis contributes to understanding the association between non-syndromic cleft lip and palate, and cancer. Mol Med Rep. 2016;13:2110–6.CrossRef Wang H, Qiu T, Shi J, Liang J, Wang Y, Quan L, Zhang Y, Zhang Q, Tao K. Gene expression profiling analysis contributes to understanding the association between non-syndromic cleft lip and palate, and cancer. Mol Med Rep. 2016;13:2110–6.CrossRef
19.
go back to reference Meng C, Wang J, Ge W, Tang S, Xu G. Correlation between CYP4F2 gene rs2108622 polymorphism and susceptibility to ischemic stroke. Int J Clin Exp Med. 2015;8:16122–6.PubMedPubMedCentral Meng C, Wang J, Ge W, Tang S, Xu G. Correlation between CYP4F2 gene rs2108622 polymorphism and susceptibility to ischemic stroke. Int J Clin Exp Med. 2015;8:16122–6.PubMedPubMedCentral
20.
go back to reference Liao D, Yi X, Zhang B, Zhou Q, Lin J. Interaction between CYP4F2 rs2108622 and CPY4A11 rs9333025 variants is significantly correlated with susceptibility to ischemic stroke and 20-Hydroxyeicosatetraenoic acid level. Genet Test Mol Biomarkers. 2016;20:223–8.CrossRef Liao D, Yi X, Zhang B, Zhou Q, Lin J. Interaction between CYP4F2 rs2108622 and CPY4A11 rs9333025 variants is significantly correlated with susceptibility to ischemic stroke and 20-Hydroxyeicosatetraenoic acid level. Genet Test Mol Biomarkers. 2016;20:223–8.CrossRef
21.
go back to reference Fu Z, Nakayama T, Sato N, Izumi Y, Kasamaki Y, Shindo A, Ohta M, Soma M, Aoi N, Sato M. A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. Am J Hypertens. 2008;21:1216–23.CrossRef Fu Z, Nakayama T, Sato N, Izumi Y, Kasamaki Y, Shindo A, Ohta M, Soma M, Aoi N, Sato M. A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. Am J Hypertens. 2008;21:1216–23.CrossRef
22.
go back to reference Vogelmeier C, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri L. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Critical Care Med. 2017;195:557–82.CrossRef Vogelmeier C, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri L. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Critical Care Med. 2017;195:557–82.CrossRef
23.
go back to reference Ding Y, Yang D, Zhou L, Xu J, Chen Y, He P, Yao J, Chen J, Niu H, Sun P. Variants in multiple genes polymorphism association analysis of COPD in the Chinese Li population. Int J Chron Obstruct Pulmon Dis. 2015;10:1455–63.CrossRef Ding Y, Yang D, Zhou L, Xu J, Chen Y, He P, Yao J, Chen J, Niu H, Sun P. Variants in multiple genes polymorphism association analysis of COPD in the Chinese Li population. Int J Chron Obstruct Pulmon Dis. 2015;10:1455–63.CrossRef
24.
go back to reference Lai G, Liu X, Wu J, Liu H, Zhao Y. Evaluation of CMV and KAP promoters for driving the expression of human CYP4F2 in transgenic mice. Int J Mol Med. 2011;29:107–12.PubMed Lai G, Liu X, Wu J, Liu H, Zhao Y. Evaluation of CMV and KAP promoters for driving the expression of human CYP4F2 in transgenic mice. Int J Mol Med. 2011;29:107–12.PubMed
25.
go back to reference Zhang JE, Klein K, Jorgensen AL, Francis B, Alfirevic A, Bourgeois S, Deloukas P, Zanger UM, Pirmohamed M. Effect of genetic variability in the CYP4F2, CYP4F11, and CYP4F12 genes on liver mRNA levels and warfarin response. Front Pharmacol. 2017;8:323.CrossRef Zhang JE, Klein K, Jorgensen AL, Francis B, Alfirevic A, Bourgeois S, Deloukas P, Zanger UM, Pirmohamed M. Effect of genetic variability in the CYP4F2, CYP4F11, and CYP4F12 genes on liver mRNA levels and warfarin response. Front Pharmacol. 2017;8:323.CrossRef
26.
go back to reference Waldman M, Peterson SJ, Arad M, Hochhauser E. The role of 20-HETE in cardiovascular diseases and its risk factors. Prostaglandins Other Lipid Mediat. 2016;125:108–17.CrossRef Waldman M, Peterson SJ, Arad M, Hochhauser E. The role of 20-HETE in cardiovascular diseases and its risk factors. Prostaglandins Other Lipid Mediat. 2016;125:108–17.CrossRef
27.
go back to reference Hoopes SL, Garcia V, Edin ML, Schwartzman ML, Zeldin DC. Vascular actions of 20-HETE. Prostaglandins Other Lipid Mediat. 2015;120:9–16.CrossRef Hoopes SL, Garcia V, Edin ML, Schwartzman ML, Zeldin DC. Vascular actions of 20-HETE. Prostaglandins Other Lipid Mediat. 2015;120:9–16.CrossRef
28.
go back to reference Parker TA, Grover TR, Kinsella JP, Falck JR, Abman SH. Inhibition of 20-HETE abolishes the myogenic response during NOS antagonism in the ovine fetal pulmonary circulation. Am J Physiol Lung Cell Mol Physiol. 2005;289:L261–7.CrossRef Parker TA, Grover TR, Kinsella JP, Falck JR, Abman SH. Inhibition of 20-HETE abolishes the myogenic response during NOS antagonism in the ovine fetal pulmonary circulation. Am J Physiol Lung Cell Mol Physiol. 2005;289:L261–7.CrossRef
29.
go back to reference Falus A, Fenyő M, Eder K, Madarasi A. Genome-wide gene expression study indicates the anti-inflammatory effect of polarized light in recurrent childhood respiratory disease. Inflamm Res. 2011;60:965–72.CrossRef Falus A, Fenyő M, Eder K, Madarasi A. Genome-wide gene expression study indicates the anti-inflammatory effect of polarized light in recurrent childhood respiratory disease. Inflamm Res. 2011;60:965–72.CrossRef
Metadata
Title
The correlation between CYP4F2 variants and chronic obstructive pulmonary disease risk in Hainan Han population
Authors
Yipeng Ding
Yixiu Yang
Quanni Li
Qiong Feng
Dongchuan Xu
Cibing Wu
Jie Zhao
Xiaoli Zhou
Huan Niu
Ping He
Jianfang Liu
Hongxia Yao
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-01348-6

Other articles of this Issue 1/2020

Respiratory Research 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.